S-1: SOBR Safe Registers Resale of Shares, Warrants

SOBR Safe, Inc. filed an S-1 registration statement for the resale of up to 3,967,746 shares of common stock, including those issuable from warrants, by selling securityholders, with no direct proceeds to the company from these sales.

Summary

• The company filed an S-1 registration statement for the resale of up to 3,967,746 shares of common stock by selling securityholders.
• This offering includes 370,000 shares of Common Stock issued under a Securities Purchase Agreement dated December 24, 2025, and up to 3,597,746 shares issuable upon the exercise of associated warrants.
• The company will not receive any cash proceeds from the sale of shares by the selling securityholders, but will receive net proceeds from any warrants exercised for cash.
• SOBR Safe, Inc. develops non-invasive technology (SOBRsafe, SOBRcheck, SOBRsure) for alcohol monitoring and detection, targeting behavioral health, judicial, commercial, and individual consumer markets.
• The company reported a 102.1% increase in revenue for the nine months ended September 30, 2025, compared to the prior year period.
• A private placement closed on December 29, 2025, generating aggregate gross proceeds of $2,000,002.20, before deducting fees and expenses.
• The company successfully exited a one-year Nasdaq monitoring period for listing compliance on October 30, 2025.
• A 1-for-10 reverse stock split was effected on April 4, 2025, reducing outstanding shares from approximately 15.2 million to 1.5 million.

Sentiment

Score: 3

Explanation: While the company reported a 102.1% revenue increase and successfully exited Nasdaq's monitoring period, it explicitly states it has 'limited revenue, and limited assets, is in unsound financial condition,' and anticipates 'significant losses for the foreseeable future.' The filing also warns that the resale of shares by selling securityholders 'will likely cause our stock price to decline' and 'could encourage short sales,' indicating substantial financial and market risks.

Positives

• Achieved a 102.1% increase in revenue for the nine months ended September 30, 2025, compared to the prior year nine-month period.
• Successfully exited the one-year Nasdaq monitoring period for listing compliance as of October 30, 2025, indicating current compliance with Nasdaq requirements.
• Received net proceeds of approximately $3.3 million from the exercise of outstanding warrants during the quarter ended March 31, 2025.
• Completed third-party hardware and sensor product validation tests in the first quarter of 2025.
• Broadened global reach of SOBRsafe users and subscribers across all 50 U.S. states, Canada, Australia, and New Zealand, including an alcohol detection program for airport personnel and pilots outside the U.S.
• Expanded business-to-business sales into the family law market in Q1 2025, addressing approximately 450,000 individuals undergoing domestic monitoring.
• Converted the company's website to an e-commerce platform, supporting both business-to-business and business-to-consumer channels for scalable sales growth.
• Launched a comprehensive customer service support center to provide a broader range of services.
• Partnering with a leading U.S. university to support research and development of a transdermal alcohol analytics platform utilizing SOBRsure devices.
• Stockholders approved an increase in authorized shares under the 2019 Equity Incentive Plan to 350,000 shares on July 17, 2025.

Negatives

• The company currently has limited revenue and assets, and is in unsound financial condition.
• Generated significant losses from operations since inception and anticipates continued significant losses for the foreseeable future.
• Success is dependent on the ability to access additional capital for various operational needs.
• The company will not receive any cash proceeds from the sale of shares by the selling securityholders in this offering.
• The resale of up to 3,967,746 shares by selling securityholders may cause the stock price to decline.
• Sale of common stock by the selling securityholders could encourage short sales by third parties, which could contribute to a further decline in the stock price.
• The company may not be able to maintain its listing on Nasdaq if it falls out of compliance with requirements like minimum bid price or stockholders' equity in the future.
• If delisted from Nasdaq and classified as a 'penny stock' (below $5.00 per share), it would become more difficult to trade shares, reducing liquidity.
• The company does not anticipate paying any cash dividends in the foreseeable future.

Risks

• Inability to maintain Nasdaq listing, which could negatively impact liquidity, market price, ability to raise equity financing, use of registration statements, and equity incentives for employees.
• Risk of common stock becoming a 'penny stock' if the market price falls below $5.00, making it more difficult to trade.
• Significant downward pressure on stock price due to the sale of a large number of shares by selling securityholders.
• Potential for increased short sales due to the resale offering, further declining stock price.
• Dependence on ability to access additional capital to offset negative cash flows, accelerate customer acquisition, fund advanced material purchasing, acquire new technology, acquire key assets, and expand sales.
• Risks in developing, marketing, and selling devices based on the SOBRsafe platform, which could impact revenue generation.
• Forward-looking statements are based on current beliefs and assumptions and are not guarantees of future performance, involving known and unknown risks and uncertainties.
• The company's ability to obtain funding for operations, including product development and commercialization.
• Timing, costs, and outcome of regulatory review.
• Ability to attract and retain key scientific and clinical personnel.
• Ability to contract with third-party suppliers and manufacturers and their adequate performance.
• Ability to establish own manufacturing facilities domestically.
• Ability to expand products into additional indications and patient populations.
• Beneficial characteristics, safety, and efficacy of products.
• Political and regulatory developments in the U.S. and other jurisdictions.
• Cost of maintaining, expanding, and enforcing intellectual property rights.
• Potential claims relating to intellectual property.
• Impact of litigation, regulatory inquiries, or investigations, and cost to indemnify officers and directors.
• Cost and timing of future commercialization activities (manufacturing, marketing, sales, distribution) for product candidates requiring regulatory approval.

Future Outlook

The company anticipates continued significant losses from operations for the foreseeable future and expects to need additional capital to offset negative cash flows, accelerate customer acquisition, fund advanced material purchases, acquire new technology, acquire key assets, and expand sales. It also anticipates needing to evolve its products and software to meet diverse customer requirements. The company believes its outsourced manufacturers can support increased sales for the foreseeable future. It is exploring possible integrations with existing systems and licensing by non-competitive third parties, believing its device portfolio could yield a substantial repository of user data, potentially monetizable for statistical analytics and enabling the development of business and insurance liability benchmarking through AI.

Management Comments

• Our mission is to save lives, positively impact behavioral outcomes and individual wellness, increase workplace safety and productivity, and create significant economic benefits.
• We believe our device portfolio approach could yield a substantial repository of user data — a potentially monetizable asset for statistical analytics.
• By demonstrating substance-free environments, organizations could deliver a data-driven argument for a reduction in annual insurance premiums.
• We anticipate that our outsourced manufacturers can adequately support an increase in sales for the foreseeable future.
• We expect that we will need to continue to evolve our products and software to meet diverse customer requirements across varied markets.
• Since inception we have generated significant losses from operations and anticipate that we will continue to generate significant losses for the foreseeable future.
• Our success is dependent on our ability to access additional capital.
• We do not believe we will be subject to any government regulation in the targeted alcohol detection markets including Behavioral Health, Justice, Alcohol Rehabilitation, Consumer, Facility & Fleet, or Young Driver markets.

Industry Context

The company operates in the alcohol detection and monitoring industry, focusing on non-invasive transdermal technology. Its products (SOBRcheck, SOBRsure) target diverse markets including behavioral health, judicial, commercial (oil & gas, fleet, telematics, ride-share, workplace safety), and individual consumer use (co-parenting, personal accountability, adolescent driver safety). The strategy involves direct sales, channel partners, and licensing/integration agreements. The emphasis on data collection and AI for insurance liability benchmarking suggests an alignment with broader trends in data-driven risk management and preventative health/safety solutions. The company's global expansion (U.S., Canada, Australia, New Zealand) and specific programs (airport personnel/pilots) indicate a broad market approach.

Comparison to Industry Standards

• The filing does not provide specific comparisons to industry standards or comparable companies/projects.
• The company highlights its 'unique Pass/Fail methodology' for alcohol detection, differentiating it from methods measuring discrete Blood Alcohol Content (BrAC) and potentially exempting it from certain government regulations in targeted markets.
• This approach suggests a differentiation strategy rather than direct benchmarking against existing industry standards or competitors' specific results.

Corporate Governance

Legal Proceedings

• The filing mentions 'the outcome of any legal proceedings that may be instituted against us' as a forward-looking statement risk, but does not detail any current specific legal proceedings.
• It also mentions 'impact of litigation, regulatory inquiries, or investigations, as well as cost to indemnify our officers and directors against third-party claims related to our patents and other intellectual property' as a risk.

Related Party Transactions

• On March 1, 2022, 3,000,000 Series B Convertible Preferred Stock shares were issued in exchange for 303 shares of common stock held by CEO David Gandini and 607 shares of common stock held by IDTEC SPV, LLC, an entity controlled by a beneficial owner of the Company. These shares were later converted to common stock on April 20, 2023.
• Steven Beabout, a Lead Independent Director, has interests in IDTEC, LLC and SOBR Safe, LLC, both of which own shares of the company's common stock, though he does not have a controlling interest in either entity.

Stakeholder Impact

• Shareholders face potential dilution from warrant exercises and the resale of shares by selling securityholders, which is explicitly stated to 'likely cause our stock price to decline.' There is also a risk of delisting from Nasdaq and becoming a 'penny stock,' which could reduce liquidity and market price. The company does not anticipate paying dividends.
• Employees' equity incentives could be impacted if the stock is delisted. The company has 17 full-time employees and utilizes professional consultants.
• Customers may benefit from continued product evolution, expansion of sales channels (e-commerce, channel partners), and the launch of a comprehensive customer service support center.
• Creditors may face concerns due to the company's 'unsound financial condition' and its dependence on 'additional capital' to fund operations.
• New investors are warned of a high degree of risk due to limited revenue, significant losses, and unsound financial condition.

Next Steps

• Continue to evolve products and software to meet diverse customer requirements across varied markets.
• Explore possible integrations with existing systems and licensing by non-competitive third parties.
• Develop business and insurance liability benchmarking through AI, leveraging user data.
• Apply for related patents to convert Provisional Patent Applications as part of patent defense strategy.
• Monitor Nasdaq listing requirements quarterly to maintain compliance.
• File post-effective amendments to the registration statement as required by the Securities Act.

Key Dates

Recommendation

The filing explicitly states the company is in 'unsound financial condition' with 'limited revenue, and limited assets,' and anticipates 'significant losses for the foreseeable future.' It also directly warns that the resale of a substantial number of shares by selling securityholders 'will likely cause our stock price to decline' and 'could encourage short sales by third parties, which could contribute to the further decline of our stock price.' These are strong indicators of severe downside risk and poor financial health, making a 'Sell' recommendation appropriate for a seasoned investor.

Keywords

Alcohol detection, Non-invasive monitoring, Workplace safety, Behavioral health, SEC filing, S-1 registration, Common stock resale, Warrants, Nasdaq listing, SOBRsafe, SOBRcheck, SOBRsure, Private placement, Reverse stock split, Financial technology, Biometric data, Transdermal alcohol screening